Castillo reveals confidence boost for cobalt mineralisation at Broken Hill

|

Published 19-MAR-2018 11:09 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Castillo Copper (ASX:CCZ) has today informed the market than an encouraging desktop report from geology consultant, Xplore Resources, has highlighted considerable potential for additional cobalt mineralisation and favourable zones of outcrops across the company’s Broken Hill Project.

This prolific NSW region is steadily emerging as a new global supply chain hub, especially given current cobalt sentiment.

CCZ’s peers, Cobalt Blue (ASX:COB) and Havilah Resources (ASX:HAV), have confirmed cobalt resources here. Alloy Resources (ASX:AYR) and Australian Mines (ASX:AUZ) have also recently revealed encouraging exploratory results.

Specifically, HAV has reported 193.3Mt at 120 parts per million of cobalt. COB’s Thackaringa resource, on the other hand, contains 54.9Mt at 910 parts per million of cobalt.

Castillo copper broken hill

Broken Hill’s location in relation to peers

Previous exploration here has primarily focused on traditional Broken Hill mineral systems – zinc, lead and gold – but with rapidly growing demand for battery grade minerals, the economics are increasingly favourable for cobalt.

With the cobalt price sitting at around US$85,000 per tonne, CCZ is keen to fast-track its exploration program to ascertain the full extent of cobalt mineralisation across the tenure, with a core focus on targeting known host mineralised areas.

Of course, as with all minerals exploration, success is not guaranteed — consider your own personal circumstances before investing, and seek professional financial advice

Interestingly, there is also material exploration upside within the tenure, as some 75 per cent is covered in alluvial sand, especially significantly where the outcrop is visible, with legacy assay results indicating the presence of cobalt.

To uncover incremental target areas of sulphide-hosted cobalt mineralisation below the alluvial sand, CCZ plans to deploy heliborne electromagnetic geophysical survey technology – this has been successfully utilised by both COB and AUZ. Also beneficial for CCZ is that extracting cobalt from sulphides is proven to be materially simpler and more cost effective than laterites.

Importantly, re-opening the Cangai Copper Mine remains CCZ’s primary focus, with the second drilling campaign set to target supergene ore – an update on legacy stockpiles is expected in the near future.

Xplore Resources are currently reviewing additional available geophysical survey data, with a further update expected shortly.

CCZ chairman, Peter Meagher, said: “With the cobalt price around US$85,000/t, the board has mandated Xplore Resources to fast-track understanding the extent of cobalt mineralisation and develop the inaugural drilling program for our Broken Hill asset.”

“Indeed, the board is cognisant the region is emerging as a new potential supply chain hub for cobalt which augurs favourably for CCZ, particularly given its proximity to peers with defined JORC resources.”

“CCZ believes focusing on reopening the Cangai Copper Mine and concurrently gaining a deeper understanding of the cobalt potential at the Broken Hill asset are key forward value drivers,” added Meagher.

tags

COBALT


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X